News June 2, 2022 Soricimed Appoints Nationally Recognized Scientific and Academic Leader, Dr. Rodney Ouellette, to its Scientific Advisory Board
News November 9, 2021 Mount Allison University to collaborate with Soricimed Biopharma Inc. on novel biopesticide solution
News January 8, 2021 Soricimed and Orano Med Announce Collaboration to Develop New Targeted Cancer Treatments
News December 17, 2020 Soricimed to Investigate the Potential Benefit of SOR-C13 in the Treatment of COVID-19
News September 29, 2020 Soricimed Continues Critical Research Thanks to Support from the Government of Canada
News June 9, 2020 Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial of SOR-C13
News February 7, 2020 Soricimed Announces Completion of First Cohort in Investigator-Initiated Phase 1b Clinical Trial of SOR-C13
News December 3, 2019 Soricimed to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
News November 26, 2019 Soricimed Announces Journal of Cancer Publication Identifying TRPV6 as a Promising Target for Cancer Therapy
News November 1, 2019 BioTuesdays video of our primary focus area, targeted drug candidates for the treatment of solid-tumor cancers.
News October 2, 2019 Chief Scientific Officer, Professor Jack Stewart discusses focus on ovarian, prostate and pancreatic cancers.
News October 2, 2019 Professor Jack Stewart, Chief Scientific Officer, explains the mechanism of action of Soricimed's lead drug candidate, SOR-C13.
News October 2, 2019 Chief Scientific Officer, Professor Jack Stewart, provides background on the investigator initiated clinical trial of SOR-C13 in late-stage pancreatic cancer.
News September 24, 2019 Soricimed Announces Initiation of Patient Dosing for First Cohort in Investigator-Initiated Phase 1b Clinical trial of SOR-C13
News September 5, 2019 Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
News August 6, 2019 Soricimed Announces Investigator Initiated Phase 1b Clinical trial of its Lead Drug Candidate in Late-Stage Pancreatic Cancer
| 
| 
| 